TITLE

Effect of CYP2C19 variants on clopidogrel

PUB. DATE
November 2009
SOURCE
Internal Medicine Alert;11/17/2009 Supplement, p21
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the results of a study which investigates the effect of CYP2C19 or P450 2C19 metabolite variants on clopidogrel.
ACCESSION #
46738315

 

Related Articles

  • Thienopyridine-proton pump inhibitor drug interaction. Polli, Stephanie Inverso // Hem/Onc Today;11/10/2009, Vol. 10 Issue 21, p5 

    The article discusses issues related to the metabolism processes of clopidogrel involving cytochrome P450 (CYP).

  • Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug-Drug Interactions. Tornio, A; Filppula, A M; Kailari, O; Neuvonen, M; Nyrönen, T H; Tapaninen, T; Neuvonen, P J; Niemi, M; Backman, J T // Clinical Pharmacology & Therapeutics;Oct2014, Vol. 96 Issue 4, p498 

    Cerivastatin and repaglinide are substrates of cytochrome P450 (CYP)2C8, CYP3A4, and organic anion-transporting polypeptide (OATP)1B1. A recent study revealed an increased risk of rhabdomyolysis in patients using cerivastatin with clopidogrel, warranting further studies on clopidogrel...

  • Paraoxonase-1 and clopidogrel efficacy. Dansette, Patrick M; Rosi, Julien; Bertho, Gildas; Mansuy, Daniel // Nature Medicine;Sep2011, Vol. 17 Issue 9, p1040 

    A letter to the editor is presented concerning the dependence of cytochrome P450 (CYP) in paraoxonase-1 (PON1) and the role of PON1 in the efficacy of clopidogrel drug.

  • Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation. Takahashi, M; Saito, T; Ito, M; Tsukada, C; Katono, Y; Hosono, H; Maekawa, M; Shimada, M; Mano, N; Oda, A; Hirasawa, N; Hiratsuka, M // Pharmacogenomics Journal;Feb2015, Vol. 15 Issue 1, p26 

    Genetic variations in cytochrome P450 2C19 (CYP2C19) contribute to interindividual variability in the metabolism of therapeutic agents such as clopidogrel. Polymorphisms in CYP2C19 are associated with large interindividual variations in the therapeutic efficacy of clopidogrel. This study...

  • Evaluation of a microarray-based genotyping assay for the rapid detection of cytochrome P450 2C19 *2 and *3 polymorphisms from whole blood using nanoparticle probes. Buchan, Blake W.; Peterson, Jess F.; Cogbill, Christopher H.; Anderson, Dennis K.; Ledford, Joellen S.; White, Mary N.; Quigley, Neil B.; Jannetto, Paul J.; Ledeboer, Nathan A. // American Journal of Clinical Pathology;Oct2011, Vol. 136 Issue 4, p604 

    Numerous drugs such as clopidogrel have been developed to reduce coagulation or inhibit platelet function. The hepatic cytochrome P450 (CYP) pathway is involved in the conversion of clopidogrel to its active metabolite. A recent black-box warning was included in the clopidogrel package insert...

  • SHORT CUTS. Fister, Kristina // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/5/2009, Vol. 339 Issue 7720, p536 

    This section discusses various health-related studies published in different journals. A study published in the "New England Journal of Medicine" estimated the cumulative doses of radiation received by patients in the U.S. during imaging procedures. Another study published in the same journal...

  • Progress of Antiplatelet Pharmacogenomics. Oestreich, Julie H. // Current Drug Targets;Nov2011, Vol. 12 Issue 12, p1848 

    Numerous genetic variants have been studied in the context of antiplatelet responsiveness, particularly for aspirin and clopidogrel. The majority of these variants have failed to demonstrate any measurable level of clinical validity with the exception of the CYP2C19*2 allele. Several studies...

  • Impact of Genetic Polymorphisms and Drug-Drug Interactions on Clopidogrel and Prasugrel Response Variability. Ancrenaz, V.; Daali, Y.; Fontana, P.; Besson, M.; Samer, C.; Dayer, P.; Desmeules, J. // Current Drug Metabolism;Oct2010, Vol. 11 Issue 8, p667 

    No abstract available.

  • Effect of CYP2C19 variants on clopidogrel.  // Clinical Cardiology Alert;Nov2009 Clinical Briefs, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics